TrHCROSS mini 2.0 %

Precision for small joints

Intra-articular injection of cross-linked hyaluronic acid using SARE Technology for small joints.

Concentration: 20 mg/mL
Presentation: 1 mL disposable, non-pyrogenic, sterile prefilled syringe with Luer lock
Certification: Class III Medical Device (MDR)
Recommended needle: 23 - 27 G
Shelf life: 2 years
Technology: SARE Technology (HA Crosslinking Tech)

SARE Technology

Reducción del dolor

Efecto duradero

Propiedades viscoelásticas

Viscosuplementación

Advantages

Manufactured in Europe to demanding quality standards.

Low endotoxin level ≤ 0.20 EU/mL.

Intra-articular durability of 6 months.

Optimal viscosity for improved adaptability in small joints.

Greater resistance to enzymatic degradation.

Helps improve the patient's symptoms.

Promotes recovery of joint function.

Indications

TrHCROSS mini 2.0% is a cross-linked HA product indicated for viscosupplementation of the synovial fluid in small diarthrodial joints, including the wrist, metacarpal joints, ankle and metatarsal joints, when viscosity has decreased due to degenerative lesions and trauma, such as osteoarthritis.

Properties

Reduces pain and stiffness in small diarthrodial joints.

Improves the function and mobility of small diarthrodial joints.

Reduces analgesic use.

Improves patients' quality of life.

Directions for use

TrHCROSS mini 2.0% must be administered intra-articularly only by healthcare professionals specialising in traumatology. Several joints may be treated at the same time.

The recommended dose of TrHCROSS mini 2.0% is 1 mL, administered as a single intra-articular injection.

Technology

SARE Technology®

An innovative hyaluronic acid cross-linking method that delivers unique results through a highly homogeneous cross-linking process.

A proprietary combination of low- and high-molecular-weight hyaluronic acid that creates a polymer matrix with a low degree of modification.